These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12172080)

  • 21. Immunologic profile of highly exposed yet HIV type 1-seronegative men.
    Yang OO; Boscardin WJ; Matud J; Hausner MA; Hultin LE; Hultin PM; Shih R; Ferbas J; Siegal FP; Shodell M; Shearer GM; Grene E; Carrington M; O'Brien S; Price CB; Detels R; Jamieson BD; Giorgi JV
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1051-65. PubMed ID: 12396457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope.
    Beretta A; Weiss SH; Rappocciolo G; Mayur R; De Santis C; Quirinale J; Cosma A; Robbioni P; Shearer GM; Berzofsky JA
    J Infect Dis; 1996 Feb; 173(2):472-6. PubMed ID: 8568315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in T-lymphocyte subsets in intravenous drug users with HIV-1 infection.
    Margolick JB; Muñoz A; Vlahov D; Solomon L; Astemborski J; Cohn S; Nelson KE
    JAMA; 1992 Mar; 267(12):1631-6. PubMed ID: 1347321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour.
    Koning FA; Jansen CA; Dekker J; Kaslow RA; Dukers N; van Baarle D; Prins M; Schuitemaker H
    AIDS; 2004 May; 18(8):1117-26. PubMed ID: 15166527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans.
    Bégaud E; Chartier L; Marechal V; Ipero J; Léal J; Versmisse P; Breton G; Fontanet A; Capoulade-Metay C; Fleury H; Barré-Sinoussi F; Scott-Algara D; Pancino G
    Retrovirology; 2006 Jun; 3():35. PubMed ID: 16792805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users.
    Scott-Algara D; Truong LX; Versmisse P; David A; Luong TT; Nguyen NV; Theodorou I; Barré-Sinoussi F; Pancino G
    J Immunol; 2003 Dec; 171(11):5663-7. PubMed ID: 14634071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection.
    Alter G; Merchant A; Tsoukas CM; Rouleau D; LeBlanc RP; Côté P; Baril JG; Thomas R; Nguyen VK; Sékaly RP; Routy JP; Bernard NF
    J Infect Dis; 2002 Mar; 185(6):755-65. PubMed ID: 11920293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals.
    Larsson M; Jin X; Ramratnam B; Ogg GS; Engelmayer J; Demoitie MA; McMichael AJ; Cox WI; Steinman RM; Nixon D; Bhardwaj N
    AIDS; 1999 May; 13(7):767-77. PubMed ID: 10357375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals.
    Furci L; Lopalco L; Loverro P; Sinnone M; Tambussi G; Lazzarin A; Lusso P
    AIDS; 2002 May; 16(7):1003-8. PubMed ID: 11953466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals.
    Restrepo C; Rallón NI; del Romero J; Rodríguez C; Hernando V; López M; Peris A; Lozano S; Sempere-Ortells JM; Soriano V; Benito JM
    J Immunol; 2010 Jul; 185(2):982-9. PubMed ID: 20543099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture.
    Guardo AC; Ruiz-Riol M; Fernández E; Maleno MJ; Bargalló ME; León A; Climent N; García F; Gatell JM; Brander C; Plana M
    AIDS; 2015 Jul; 29(11):1309-18. PubMed ID: 26091301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons.
    Bernard NF; Pederson K; Chung F; Ouellet L; Wainberg MA; Tsoukas CM
    AIDS; 1998 Nov; 12(16):2125-39. PubMed ID: 9833853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates.
    Cameron B; Galbraith S; Li H; Lloyd A;
    J Viral Hepat; 2013 Apr; 20(4):e96-106. PubMed ID: 23490396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-specific T helper responses and frequency of exposure among HIV-exposed seronegative female sex workers in Abidjan, Cote d'Ivoire.
    Jennes W; Vuylsteke B; Borget MY; Traore-Ettiegne V; Maurice C; Nolan M; Nkengasong JN; Kestens L
    J Infect Dis; 2004 Feb; 189(4):602-10. PubMed ID: 14767812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users.
    Barcellini W; Rizzardi GP; Velati C; Borghi MO; Fain C; Lazzarin A; Meroni PL
    AIDS; 1995 Jul; 9(7):691-4. PubMed ID: 7546412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
    Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
    J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune defence against HIV-1 infection in HIV-1-exposed seronegative persons.
    Schmechel SC; Russell N; Hladik F; Lang J; Wilson A; Ha R; Desbien A; McElrath MJ
    Immunol Lett; 2001 Nov; 79(1-2):21-7. PubMed ID: 11595286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of prolonged immunosilent infection with human immunodeficiency virus in individuals with high-risk behaviors.
    Coutlée F; Olivier C; Cassol S; Voyer H; Kessous-Elbaz A; Saint-Antoine P; He Y; Fauvel M
    Am J Med; 1994 Jan; 96(1):42-8. PubMed ID: 8304362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of hepatitis C virus genotypes among intravenous drug users. A ten-year study in Palermo, Sicily.
    Vitale F; Villafrate MR; Viviano E; Perna AM; Bonura F; Di Benedetto MA; Mazzola G; Colletti P; Prestileo T; Romano N
    New Microbiol; 1998 Oct; 21(4):335-42. PubMed ID: 9812314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood.
    Clerici M; Levin JM; Kessler HA; Harris A; Berzofsky JA; Landay AL; Shearer GM
    JAMA; 1994 Jan; 271(1):42-6. PubMed ID: 8258885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.